Veracyte
Veracyte to Acquire HalioDx for €260M
Veracyte said the acquisition will help accelerate its in vitro diagnostic test development and manufacturing operations in Europe.
In Brief This Week: Merck, Clovis Oncology, Grail, GenomOncology, Veracyte, Amoy Diagnostics
News items for the week of March 15, 2021.Â
Decipher will remain a wholly owned subsidiary of Veracyte, which plans to integrate Decipher's urologic cancer tests on its nCounter platform.
Veracyte to Acquire Decipher Biosciences for $600M; Prelim Q4 Revenues Grow 14 to 18 Percent
San Diego-based Decipher has a portfolio of genomic tests for urologic cancers to improve patient decision-making and accelerate adoption of new therapies. Â Â
Bayer, Veracyte to Identify Therapy-Resistant Thyroid Cancer Patients
Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.